brs0660
supremo
- Joined
- May 24, 2009
- Messages
- 2,125
- Age
- 77
- Location
- Durham, North Carolina
- Country
- United States
- Gender
- Female
Tramadol (Ultram and Ultracet) Linked to Risk for Serotonin Syndrome
On September 9, the FDA approved safety labeling revisions for tramadol HCl (marketed alone and with acetaminophen as Ultram and Ultracet tablets by Ortho McNeil Pharmaceuticals) to warn of the potential risk for potentially life-threatening serotonin syndrome.
Serotonin syndrome may occur with use of tramadol alone but particularly in combination with use of serotonergic drugs such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and triptans; drugs that inhibit serotonin metabolism, including MAOIs; and drugs that impair the metabolism of tramadol, such as cytochrome P 450 isoenzyme 2D6 (CYP 2D6) and CYP 3A4 inhibitors. Adverse events may occur at the recommended tramadol dose, the FDA said.
Symptoms of serotonin syndrome may include mental status changes (eg, agitation, hallucinations, and coma), autonomic instability (eg, tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (eg, hyperreflexia and incoordination), and/or gastrointestinal tract symptoms (eg, nausea, vomiting, and diarrhea).
Tramadol is indicated for the management of moderate to moderately severe pain in adults. Administered as a combination tablet with acetaminophen, tramadol is indicated for the short-term (≤ 5 days) management of acute pain.
Information taken from Medscape CME website
On September 9, the FDA approved safety labeling revisions for tramadol HCl (marketed alone and with acetaminophen as Ultram and Ultracet tablets by Ortho McNeil Pharmaceuticals) to warn of the potential risk for potentially life-threatening serotonin syndrome.
Serotonin syndrome may occur with use of tramadol alone but particularly in combination with use of serotonergic drugs such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and triptans; drugs that inhibit serotonin metabolism, including MAOIs; and drugs that impair the metabolism of tramadol, such as cytochrome P 450 isoenzyme 2D6 (CYP 2D6) and CYP 3A4 inhibitors. Adverse events may occur at the recommended tramadol dose, the FDA said.
Symptoms of serotonin syndrome may include mental status changes (eg, agitation, hallucinations, and coma), autonomic instability (eg, tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (eg, hyperreflexia and incoordination), and/or gastrointestinal tract symptoms (eg, nausea, vomiting, and diarrhea).
Tramadol is indicated for the management of moderate to moderately severe pain in adults. Administered as a combination tablet with acetaminophen, tramadol is indicated for the short-term (≤ 5 days) management of acute pain.
Information taken from Medscape CME website